Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
David Van Wagoner, PhD, is a Translational Scientist who works with physicians in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic. As a scientist, Dr. Van Wagoner does not treat patients, but works closely with Heart Center physicians to research the mechanisms underlying atrial fibrillation, and to develop and assess new techniques for treating atrial fibrillation and other aging-related cardiovascular conditions. Dr. Van Wagoner's specialty is cellular electrophysiology research.
Dr. Van Wagoner received his PhD in pharmacology from Thomas Jefferson University in Philadelphia in 1985. He received NIH-supported postdoctoral training in the Department of Biochemistry and Biophysics at the University of Pennsylvania. He was a Research Associate at Case Western Reserve University before becoming a Project Scientist in the Departments of Cardiology and Molecular Cardiology at Cleveland Clinic in 1988. In 2000, he became Director of the Cleveland Clinic's Basic Cardiac Electrophysiology Laboratory.
Dr. Van Wagoner's cardiac electrophysiology research program is primarily funded by the National Institutes of Health, but has also received support from the American Heart Association, the Atrial Fibrillation Innovation Center, the Fondation Leducq European-North American Research Alliance and several pharmaceutical companies. His research focused on human atrial fibrillation is highly collaborative and translational, with extensive interactions both with cardiac surgeons in the Department of Cardiothoracic Surgery and cardiologists in the Section of Electrophysiology in the Department of Cardiovascular Medicine. Recent studies have examined the role of oxidative stress in the electrophysiological remodeling associated with atrial fibrillation, the mechanisms underlying postoperative atrial fibrillation and the relationship between the systemic inflammatory response and persistence of atrial fibrillation.
Dr. Van Wagoner is an active member of the Faculty of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is widely published in professional cardiology, electrophysiology and physiology journals including Circulation, Circulation Research, and the American Journal of Physiology. He is a member of the editorial board of several cardiovascular journals and is a reviewer for national and international medical publications and funding agencies. Dr. Van Wagoner is a member of numerous professional societies including the American Physiological Society, the American Society of Pharmacology and Experimental Therapeutics, and the North American Society of Pacing and Electrophysiology. He is a Fellow of the Basic Cardiovascular Sciences Council of the American Heart Association.
Dr. Van Wagoner is frequently an invited speaker on atrial fibrillation and other cardiovascular topics at national and international symposia and conferences.
cardiac electrophysiology, atrial fibrillation, arrhythmia mechanisms
Awards & Honors
Core member of the Fondation Leducq European-North American Atrial Fibrillation Research Alliance
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/1/2016, Dr. Van Wagoner has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.